Return-Path: Received: from [2607:fb91:8c1b:8c8::f0:ffff] ([2607:fb91:8c1b:8c8:5cd6:2797:a597:d454]) by smtp.gmail.com with ESMTPSA id 956f58d0204a3-65314b25fa8sm10638652d50.1.2026.04.24.06.42.45 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Fri, 24 Apr 2026 06:42:46 -0700 (PDT) Date: Fri, 24 Apr 2026 09:42:34 -0400 From: tjphuhs@gmail.com To: "=?utf-8?Q?oc.tjphuhs=40gmail.com?=" Message-ID: <571fbb9b-896c-4025-853c-1dad98cd5245@Spark> In-Reply-To: <20260424130546.3.5a96bbcb7b290f46@mg-d0.substack.com> References: <20260424130546.3.5a96bbcb7b290f46@mg-d0.substack.com> Subject: Fwd: Eli =?utf-8?Q?Lilly=E2=80=99s_?=Quintuple Agonist: The Next Frontier in Metabolic Medicine X-Readdle-Message-ID: 571fbb9b-896c-4025-853c-1dad98cd5245@Spark MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="69eb7354_7ef7f3d0_1f43" --69eb7354_7ef7f3d0_1f43 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable Content-Disposition: inline ---------- =46orwarded message ---------- =46rom: Derek from Research Radar Date: Apr 24, 2026 at 9:10=E2=80=AFAM -0400 To: tjphuhs=40gmail.com Subject: Eli Lilly=E2=80=99s Quintuple Agonist: The Next =46rontier in Me= tabolic Medicine > Let=E2=80=99s talk about one of the biggest stories currently brewing i= n the obesity and metabolic disease space =E2=80=94 Eli Lilly=E2=80=99s r= umored quintuple agonist. > =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD > =46orwarded this email=3F Subscribe here for more > Eli Lilly=E2=80=99s Quintuple Agonist: The Next =46rontier in Metabolic= Medicine > Derek > Apr 24 > > READ IN APP > > Let=E2=80=99s talk about one of the biggest stories currently brewing i= n the obesity and metabolic disease space =E2=80=94 Eli Lilly=E2=80=99s r= umored quintuple agonist. If you=E2=80=99ve been on peptide Twitter, Redd= it, or Instagram the last few weeks, you=E2=80=99ve seen the hype. Animal= data reportedly dropping at ADA on May 29, 2026. =46ive receptors hit by= a single molecule. The next step beyond retatrutide. > Upgrade to paid > I want to walk through what=E2=80=99s actually going on here, because t= here=E2=80=99s real, exciting science behind this AND there=E2=80=99s a l= ot of social media buzz that=E2=80=99s getting mashed together. The mecha= nism is fascinating, the trajectory of the field is remarkable, and calci= tonin in particular could solve problems nobody has solved yet. > This post is going to cover what a quintuple agonist actually is, why t= he field is moving in this direction, what each of the five receptors doe= s, what=E2=80=99s confirmed versus what=E2=80=99s hype, and why time is t= he most important variable in all of this. Grab a coffee. > As always, this is research use only. Nothing here is medical advice. > =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 > WHAT IS A QUINTUPLE AGONIST=3F > A quintuple agonist is a single molecule engineered to activate five di= fferent receptors in the body simultaneously. To understand why that matt= ers, you need to understand one key concept first. > An agonist is a compound that activates a receptor. Think of receptors = like switches on the surface of your cells =E2=80=94 an agonist walks up = and flips the switch ON, which triggers whatever that switch controls. Ap= petite, blood sugar regulation, fat burning, satiety, and so on. > Here=E2=80=99s the progression of how this field has evolved: > > =E2=80=A2 > Semaglutide (Ozempic, Wegovy) activates 1 receptor (GLP-1) > =E2=80=A2 > Tirzepatide (Mounjaro, Zepbound) activates 2 receptors (GLP= -1, GIP) > =E2=80=A2 > Retatrutide activates 3 receptors (GLP-1, GIP, glucagon) > =E2=80=A2 > A quintuple agonist would activate 5 receptors in one molec= ule > > Each generation has meaningfully outperformed the last. Semaglutide pro= duces around 15% weight loss. Tirzepatide pushed that to around 22.5% at = 72 weeks. Retatrutide hit 28.7% at 68 weeks in its Phase 3 trial. The ide= a behind the quintuple is to stack even more metabolic pathways into a si= ngle dose and push efficacy into territory that previously only bariatric= surgery could reach. > =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 > THE =46IVE RECEPTORS AND WHY EACH MATTERS > The rumored Lilly quintuple reportedly targets GLP-1, GIP, glucagon, am= ylin, and calcitonin. Let=E2=80=99s break down what each one actually doe= s. > GLP-1 (Glucagon-Like Peptide-1) > This is the backbone of every modern weight loss drug, from semaglutide= forward. GLP-1 stimulates insulin release when blood sugar is high, supp= resses glucagon (preventing unnecessary sugar release from the liver), an= d slows gastric emptying so you feel full longer. It also acts directly o= n the brain=E2=80=99s appetite centers in the hypothalamus, reducing hung= er and food reward signaling. This is why semaglutide alone can drive 15%= weight loss =E2=80=94 GLP-1 is incredibly powerful on its own. > GIP (Glucose-Dependent Insulinotropic Polypeptide) > =46or decades, GIP was considered a =E2=80=9Cbad=E2=80=9D hormone becau= se it was associated with fat storage. Tirzepatide flipped that narrative= . It turns out that when you activate GIP alongside GLP-1, you get signif= icantly better weight loss AND better tolerability with less nausea. GIP = enhances insulin sensitivity, supports GLP-1=E2=80=99s appetite effects, = and appears to help the body handle nutrients more efficiently. The syner= gy between GLP-1 and GIP is why tirzepatide outperformed semaglutide so d= ramatically. > Glucagon > This is the =E2=80=9Cburn fat for fuel=E2=80=9D switch. Glucagon recept= or activation increases energy expenditure =E2=80=94 meaning your body bu= rns more calories at rest =E2=80=94 promotes fat breakdown in the liver a= nd adipose tissue, and improves lipid profiles and liver health. The tric= ky part is glucagon also raises blood sugar, which is why you can=E2=80=99= t use it alone. But when you pair it with GLP-1 and GIP (which both lower= blood sugar), the net effect is a metabolic powerhouse =E2=80=94 you=E2=80= =99re suppressing appetite AND torching calories at the same time. This i= s why retatrutide has shown such strong results in fatty liver disease (M= ASLD) in addition to weight loss. > Amylin > Amylin is a hormone your pancreas releases alongside insulin after meal= s. It complements the incretin effects through a different pathway: > > =E2=80=A2 > Slows gastric emptying through a distinct mechanism from GL= P-1 > =E2=80=A2 > Reduces glucagon release after meals > =E2=80=A2 > Acts on the brain to promote satiety > =E2=80=A2 > Tends to have better tolerability than incretins, with less= nausea > > Lilly=E2=80=99s eloralintide (a selective amylin agonist) showed up to = 20.1% weight loss at 48 weeks in Phase 2 =E2=80=94 as a standalone drug. = Novo Nordisk=E2=80=99s CagriSema combines semaglutide with an amylin agon= ist for this exact reason. Amylin is a proven target. > Calcitonin > This is the most interesting addition, and the one most worth understan= ding in depth. > Calcitonin is a hormone your thyroid produces that=E2=80=99s been known= for decades primarily for calcium regulation and bone health. But over t= he last 10-15 years, researchers have discovered it has major metabolic e= ffects. Here=E2=80=99s why stacking it matters: > > =E2=80=A2 > Works with amylin but through different selectivity. Amylin= and calcitonin activate receptors in the same family but hit them with d= ifferent profiles, so stacking them gives broader, more sustained satiety= signaling than either alone. This is the logic behind DACRAs (Dual Amyli= n and Calcitonin Receptor Agonists) like KBP-042 and KBP-089, which showe= d stronger weight loss and glucose control than pure amylin agonists in p= reclinical and early human trials. > =E2=80=A2 > Improves insulin sensitivity. Calcitonin receptor activatio= n improves insulin sensitivity in muscle and fat tissue through a differe= nt pathway than GLP-1 or GIP. Complementary mechanisms stacked, not dupli= cated. > =E2=80=A2 > Potential bone protection, which is huge. Rapid weight loss= from drugs like retatrutide and tirzepatide causes meaningful bone densi= ty loss. It=E2=80=99s a known side effect of losing weight fast, regardle= ss of how you do it. Calcitonin=E2=80=99s classical role is protecting bo= ne by inhibiting bone resorption. A calcitonin component could theoretica= lly offset that bone loss, which would be a massive clinical advantage. > =E2=80=A2 > Possible cartilage protection. Early evidence suggests calc= itonin receptor activation has anti-inflammatory and cartilage-protective= effects, particularly relevant given retatrutide=E2=80=99s strong knee o= steoarthritis data. Could be a natural fit for that indication. > > So calcitonin isn=E2=80=99t just =E2=80=9Cbonus satiety.=E2=80=9D It=E2= =80=99s potentially the piece that solves some of the biggest unsolved pr= oblems with the current generation of weight loss drugs. > =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 > WHY THE =46ULL STACK MAKES SENSE > When you look at what each receptor brings to the table in the rumored = quintuple, the design philosophy becomes clear: > > =E2=80=A2 > GLP-1 and GIP give core appetite and blood sugar control (t= he tirzepatide backbone) > =E2=80=A2 > Adding glucagon brings fat-burning and energy expenditure (= the retatrutide upgrade) > =E2=80=A2 > Adding amylin brings extended satiety and slowed gastric em= ptying from a different pathway > =E2=80=A2 > Adding calcitonin brings longer-duration satiety, insulin s= ensitivity, and bone/joint protection > > On paper, you=E2=80=99d be combining the best of everything that=E2=80=99= s already working. The incretin backbone of tirzepatide, the glucagon fat= -burning of retatrutide, and the amylin/calcitonin satiety plus bone prot= ection of the DACRA class =E2=80=94 all in one molecule. The mechanism ma= kes sense, which is a big part of why people are excited. > =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 > WHAT=E2=80=99S CON=46IRMED VS. WHAT=E2=80=99S HYPE > Here=E2=80=99s where I want to pump the brakes a little. > The Lilly Quintuple Story (Mostly Hype Right Now) > The version circulating on X, Reddit (r/GLP1ResearchTalk), and Instagra= m reels claims Lilly is unveiling animal data on a GLP-1/GIP/glucagon/amy= lin/calcitonin quintuple at ADA Scientific Sessions on May 29, 2026. > The reality check: > > =E2=80=A2 > No official Eli Lilly press release exists for this compoun= d > =E2=80=A2 > No pipeline entry exists on Lilly=E2=80=99s public pipeline= page > =E2=80=A2 > No named compound (no LY-number) has been disclosed > =E2=80=A2 > The buzz traces back to a handful of social media accounts = that got amplified > > That doesn=E2=80=99t mean it=E2=80=99s fake. Lilly doesn=E2=80=99t anno= unce preclinical assets until they have data in hand, so it=E2=80=99s ent= irely plausible something drops at ADA. They already own amylin chemistry= through eloralintide, and they=E2=80=99ve proven they can design unimole= cular polyagonists. The pieces are there. > But =E2=80=9Cplausible=E2=80=9D is not the same as =E2=80=9Cconfirmed.=E2= =80=9D > The Other Quintuple That=E2=80=99s Real (And Worth Knowing About) > There=E2=80=99s a second quintuple in the literature that=E2=80=99s alr= eady published, and it proves the concept works in principle. > It was presented at EASD 2025 in Vienna by Dr. Daniela Liskiewicz from = Helmholtz Zentrum M=C3=BCnchen. That molecule targets GLP-1 + GIP + pan-P= PAR (alpha, delta, gamma =E2=80=94 three PPAR isoforms =3D five total tar= gets). It uses a clever delivery mechanism where the PPAR part is only re= leased inside cells that express GLP-1 or GIP receptors, so it=E2=80=99s = targeted rather than systemic. > Mouse models showed it outperformed GLP-1/GIP co-agonism alone on both = weight and glucose control. > This is academic preclinical work =E2=80=94 not owned by Lilly, not in = human trials =E2=80=94 but it demonstrates that pushing past three recept= or targets is a legitimate and productive research direction. Different c= ompound, same direction of travel. > =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 > THE CURRENT LANDSCAPE =E2=80=94 WHAT=E2=80=99S ACTUALLY IN TRIALS > To keep perspective on where the quintuple fits in, here=E2=80=99s what= =E2=80=99s actually advancing right now. > Retatrutide (Triple Agonist) > The most advanced next-generation obesity drug currently in human trial= s. > > =E2=80=A2 > TRIUMPH-4 (Phase 3, December 2025): 28.7% weight loss at 68= weeks on the 12mg dose, vs. 2.1% for placebo. Also delivered 76% improve= ment in WOMAC knee pain scores. > =E2=80=A2 > TRANSCEND-T2D-1 (Phase 3, March 2026): Up to 2.0% A1C reduc= tion and 16.8% weight loss at 40 weeks in type 2 diabetes patients > =E2=80=A2 > 7 additional Phase 3 readouts expected throughout 2026 > =E2=80=A2 > Likely 2027 =46DA approval per GlobalData forecasts > =E2=80=A2 > Notable safety signal: dysesthesia in 20.9% of patients on = the 12mg dose > > Eloralintide (Amylin Agonist) > Lilly=E2=80=99s selective amylin agonist, building the case for amylin = as a standalone and combination target. > > =E2=80=A2 > Phase 2 (November 2025): 9.5% to 20.1% weight loss at 48 we= eks > =E2=80=A2 > Phase 3 enrollment planned by end of 2025 > =E2=80=A2 > Being evaluated both as monotherapy and complementary to in= cretin therapy > > Orforglipron (Oral GLP-1) > Lilly=E2=80=99s small-molecule oral GLP-1 agonist, approved in April 20= 26 under the name =46oundayo. > > =E2=80=A2 > =46irst oral GLP-1 that can be taken without food or water = restrictions > =E2=80=A2 > ATTAIN-1 Phase 3: 12.4% weight loss (27.3 lbs) at 72 weeks = at the 36mg dose > =E2=80=A2 > =46DA approved for obesity in April 2026 =E2=80=94 fastest = NME approval since 2002 > > This is the actual current pipeline. The quintuple, if it=E2=80=99s rea= l, sits well behind all of these. > =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 > WHY TIME IS THE KEY VARIABLE > Here=E2=80=99s what matters most for anyone following this story. The e= xcitement is warranted, but the timeline is not short. > If animal data drops at ADA in 5 weeks, that=E2=80=99s mouse data. =46r= om mouse preclinical to approved human drug is historically 8-12 years. E= ven in this accelerated environment, we=E2=80=99re talking years before a= ny of this matters clinically. > Retatrutide itself isn=E2=80=99t approved yet. It has seven more Phase = 3 readouts coming in 2026, with likely 2027 =46DA approval. The triple ag= onist is the story of the next 12-18 months. The quintuple is the story o= f the early 2030s at the earliest. > Many preclinical compounds never make it to humans. The history of drug= development is full of animal models that looked amazing and then failed= in translation. We should expect that possibility with any new molecule.= > The dysesthesia signal in retatrutide =E2=80=94 the abnormal sensation = side effect that appeared in 20.9% of patients on the highest dose =E2=80= =94 shows that even well-designed polyagonists can surface new safety sig= nals when they hit humans. More receptor targets means more potential for= unexpected interactions. That=E2=80=99s a real consideration for the qui= ntuple concept. > =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 > A NOTE =46OR THE RESEARCH PEPTIDE COMMUNITY > I already know what=E2=80=99s coming =E2=80=94 people are going to star= t searching for =E2=80=9Cquintuple agonist=E2=80=9D on vendor sites after= this buzz. > Don=E2=80=99t waste your time. If you see one listed, it=E2=80=99s fake= . There=E2=80=99s no public sequence, no structure, nothing to verify aga= inst. Anyone claiming to have a quintuple right now is selling you vibes.= > The research peptide market always follows clinical science with a lag:= > > =E2=80=A2 > Retatrutide is only now becoming broadly available because = the sequence has been public for years > =E2=80=A2 > Tirzepatide took time after Phase 2 data came out > =E2=80=A2 > Any real quintuple =E2=80=94 even if Lilly announces someth= ing verifiable in May =E2=80=94 wouldn=E2=80=99t be meaningfully accessib= le in the research space for a long time > =E2=80=A2 > Anything claiming to be a quintuple before that is a scam > > =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 > BOTTOM LINE > The progression from dual to triple to quintuple is one of the most exc= iting trajectories in modern metabolic medicine. > What makes the quintuple concept interesting: > > =E2=80=A2 > Each receptor in the rumored stack solves a distinct proble= m > =E2=80=A2 > The mechanisms are complementary, not redundant > =E2=80=A2 > Calcitonin specifically could address issues nobody has sol= ved yet =E2=80=94 bone density loss from rapid weight loss, durability of= appetite suppression, and joint protection > =E2=80=A2 > The trajectory of the field supports the idea that more tar= gets, carefully combined, can push efficacy higher > > What to keep in mind: > > =E2=80=A2 > The Lilly quintuple is currently social media buzz, not con= firmed pipeline > =E2=80=A2 > Even if animal data drops at ADA in 5 weeks, it=E2=80=99s s= till mouse data > =E2=80=A2 > Mouse-to-market is typically 8-12 years > =E2=80=A2 > Retatrutide is what=E2=80=99s actually arriving soon > =E2=80=A2 > Eloralintide is what=E2=80=99s actually advancing through P= hase 3 for amylin > =E2=80=A2 > The quintuple, if real, is a late-decade story > > The most important thing to do right now is stay curious and stay patie= nt. Let the science play out. Don=E2=80=99t build expectations around com= pounds that haven=E2=80=99t even had human trials yet. I=E2=80=99ll cover= whatever drops at ADA on May 29 when it happens. > =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 > KEY RE=46ERENCES (=46OR DEEPER READING) > > =E2=80=A2 > Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retat= rutide for Obesity =E2=80=94 A Phase 2 Trial. N Engl J Med. 2023;389:514-= 526 > =E2=80=A2 > Eli Lilly. Retatrutide TRIUMPH-4 Phase 3 results press rele= ase. December 11, 2025. investor.lilly.com > =E2=80=A2 > Eli Lilly. Retatrutide TRANSCEND-T2D-1 Phase 3 results pres= s release. March 19, 2026. investor.lilly.com > =E2=80=A2 > Eli Lilly. Eloralintide Phase 2 results press release (publ= ished simultaneously in The Lancet). November 2025 > =E2=80=A2 > Liskiewicz D, et al. GLP-1R/GIPR/Pan-PPAR quintuple agonist= presentation. EASD 2025 Annual Meeting, Vienna > =E2=80=A2 > Medscape coverage: =E2=80=9CNovel Quintuple Agonist for Wei= ght Loss, Glucose Control=3F=E2=80=9D September 29, 2025. medscape.com > =E2=80=A2 > News-Medical coverage: =E2=80=9CNew quintuple agonist shows= promise for treating obesity and type 2 diabetes.=E2=80=9D September 21,= 2025. news-medical.net > =E2=80=A2 > Andreassen KV, et al. Research on Dual Amylin and Calcitoni= n Receptor Agonists (DACRAs, KBP-042, KBP-089) =E2=80=94 various publicat= ions > =E2=80=A2 > Eli Lilly pipeline page (no quintuple currently listed): li= lly.com/science/research-development/pipeline > > =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 > =46or research use only. Not intended for human consumption or medical = use. Always consult qualified professionals regarding any health-related = decisions. > Upgrade to paid > You're currently a free subscriber to Research Radar. =46or the full ex= perience, upgrade your subscription. > Upgrade to paid > > Share > > > Like > Comment > Restack > > =C2=A9 2026 Derek Pruski > 548 Market Street PMB 72296, San =46rancisco, CA 94104 > Unsubscribe --69eb7354_7ef7f3d0_1f43 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable Content-Disposition: inline
---------- =46orwarded message ----= ------
=46rom: Derek from Research Radar <derekpruski=40substack.com&g= t;
Date: Apr 24, 2026 at 9:10=E2=80=AFAM -0400
To: tjphuhs=40gmail.com
Subject: Eli Lilly=E2=80=99s Quintuple Agonist: The Next =46rontie= r in Metabolic Medicine

3D=22=22
Let=E2=80=99s talk about one of the biggest stories currently br= ewing in the obesity and metabolic disease space =E2=80=94 Eli Lilly=E2=80= =99s rumored quintuple agonist.
=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD
=46orwarded this email=3F Subscribe here for more

Eli Lilly=E2=80=99s Quintuple Agonist: The Next =46rontier in Metabolic = Medicine

Derek
&=23160;=
3D=22=22
3D=22=22
3D=22=22
3D=22=22
READ IN APP3D=
&=23160;=

Let=E2=80=99s talk about one of the bigg= est stories currently brewing in the obesity and metabolic disease space = =E2=80=94 Eli Lilly=E2=80=99s rumored quintuple agonist. If you=E2=80=99v= e been on peptide Twitter, Reddit, or Instagram the last few weeks, you=E2= =80=99ve seen the hype. Animal data reportedly dropping at ADA on May 29,= 2026. =46ive receptors hit by a single molecule. The next step beyond re= tatrutide.

3D=22=22
Upgrade to p= aid

I want to walk through what=E2=80=99s actually going o= n here, because there=E2=80=99s real, exciting science behind this AND th= ere=E2=80=99s a lot of social media buzz that=E2=80=99s getting mashed to= gether. The mechanism is fascinating, the trajectory of the field is rema= rkable, and calcitonin in particular could solve problems nobody has solv= ed yet.

This post is going to cover what a quintuple agonist a= ctually is, why the field is moving in this direction, what each of the f= ive receptors does, what=E2=80=99s confirmed versus what=E2=80=99s hype, = and why time is the most important variable in all of this. Grab a coffee= .

As always, this is research use only. Nothing here is = medical advice.

=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=

WHAT IS A QUINTUPLE AGONIST=3F

A quintuple agonist is a single molecule engineered to= activate five different receptors in the body simultaneously. To underst= and why that matters, you need to understand one key concept first.

An agonist is a compound that activates a receptor. Th= ink of receptors like switches on the surface of your cells =E2=80=94 an = agonist walks up and flips the switch ON, which triggers whatever that sw= itch controls. Appetite, blood sugar regulation, fat burning, satiety, an= d so on.

Here=E2=80=99s the progression of how this field has e= volved:

  • Semag= lutide (Ozempic, Wegovy) activates 1 receptor (GLP-1)

  • Tirze= patide (Mounjaro, Zepbound) activates 2 receptors (GLP-1, GIP)

  • Retat= rutide activates 3 receptors (GLP-1, GIP, glucagon)

  • A qui= ntuple agonist would activate 5 receptors in one molecule

Each generation has meaningfully outperformed the last= . Semaglutide produces around 15% weight loss. Tirzepatide pushed that to= around 22.5% at 72 weeks. Retatrutide hit 28.7% at 68 weeks in its Phase= 3 trial. The idea behind the quintuple is to stack even more metabolic p= athways into a single dose and push efficacy into territory that previous= ly only bariatric surgery could reach.

=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=

THE =46IVE RECEPTORS AND WHY EACH MATTERS

The rumored Lilly quintuple reportedly targets GLP-1, = GIP, glucagon, amylin, and calcitonin. Let=E2=80=99s break down what each= one actually does.

GLP-1 (Glucagon-Like Peptide-1)

This is the backbone of every modern weight loss drug,= from semaglutide forward. GLP-1 stimulates insulin release when blood su= gar is high, suppresses glucagon (preventing unnecessary sugar release fr= om the liver), and slows gastric emptying so you feel full longer. It als= o acts directly on the brain=E2=80=99s appetite centers in the hypothalam= us, reducing hunger and food reward signaling. This is why semaglutide al= one can drive 15% weight loss =E2=80=94 GLP-1 is incredibly powerful on i= ts own.

GIP (Glucose-Dependent Insulinotropic Polypeptide)

=

=46or decades, GIP was considered a =E2=80=9Cbad=E2=80= =9D hormone because it was associated with fat storage. Tirzepatide flipp= ed that narrative. It turns out that when you activate GIP alongside GLP-= 1, you get significantly better weight loss AND better tolerability with = less nausea. GIP enhances insulin sensitivity, supports GLP-1=E2=80=99s a= ppetite effects, and appears to help the body handle nutrients more effic= iently. The synergy between GLP-1 and GIP is why tirzepatide outperformed= semaglutide so dramatically.

Glucagon

This is the =E2=80=9Cburn fat for fuel=E2=80=9D switch= . Glucagon receptor activation increases energy expenditure =E2=80=94 mea= ning your body burns more calories at rest =E2=80=94 promotes fat breakdo= wn in the liver and adipose tissue, and improves lipid profiles and liver= health. The tricky part is glucagon also raises blood sugar, which is wh= y you can=E2=80=99t use it alone. But when you pair it with GLP-1 and GIP= (which both lower blood sugar), the net effect is a metabolic powerhouse= =E2=80=94 you=E2=80=99re suppressing appetite AND torching calories at t= he same time. This is why retatrutide has shown such strong results in fa= tty liver disease (MASLD) in addition to weight loss.

Amylin

Amylin is a hormone your pancreas releases alongside i= nsulin after meals. It complements the incretin effects through a differe= nt pathway:

  • Slows= gastric emptying through a distinct mechanism from GLP-1

  • Reduc= es glucagon release after meals

  • Acts = on the brain to promote satiety

  • Tends= to have better tolerability than incretins, with less nausea

Lilly=E2=80=99s eloralintide (a selective amylin agoni= st) showed up to 20.1% weight loss at 48 weeks in Phase 2 =E2=80=94 as a = standalone drug. Novo Nordisk=E2=80=99s CagriSema combines semaglutide wi= th an amylin agonist for this exact reason. Amylin is a proven target.

Calcitonin

This is the most interesting addition, and the one mos= t worth understanding in depth.

Calcitonin is a hormone your thyroid produces that=E2=80= =99s been known for decades primarily for calcium regulation and bone hea= lth. But over the last 10-15 years, researchers have discovered it has ma= jor metabolic effects. Here=E2=80=99s why stacking it matters:

  • Works= with amylin but through different selectivity. Amylin and calcitonin act= ivate receptors in the same family but hit them with different profiles, = so stacking them gives broader, more sustained satiety signaling than eit= her alone. This is the logic behind DACRAs (Dual Amylin and Calcitonin Re= ceptor Agonists) like KBP-042 and KBP-089, which showed stronger weight l= oss and glucose control than pure amylin agonists in preclinical and earl= y human trials.

  • Impro= ves insulin sensitivity. Calcitonin receptor activation improves insulin = sensitivity in muscle and fat tissue through a different pathway than GLP= -1 or GIP. Complementary mechanisms stacked, not duplicated.

  • Poten= tial bone protection, which is huge. Rapid weight loss from drugs like re= tatrutide and tirzepatide causes meaningful bone density loss. It=E2=80=99= s a known side effect of losing weight fast, regardless of how you do it.= Calcitonin=E2=80=99s classical role is protecting bone by inhibiting bon= e resorption. A calcitonin component could theoretically offset that bone= loss, which would be a massive clinical advantage.

  • Possi= ble cartilage protection. Early evidence suggests calcitonin receptor act= ivation has anti-inflammatory and cartilage-protective effects, particula= rly relevant given retatrutide=E2=80=99s strong knee osteoarthritis data.= Could be a natural fit for that indication.

So calcitonin isn=E2=80=99t just =E2=80=9Cbonus satiet= y.=E2=80=9D It=E2=80=99s potentially the piece that solves some of the bi= ggest unsolved problems with the current generation of weight loss drugs.=

=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=

WHY THE =46ULL STACK MAKES SENSE

When you look at what each receptor brings to the tabl= e in the rumored quintuple, the design philosophy becomes clear:

  • GLP-1= and GIP give core appetite and blood sugar control (the tirzepatide back= bone)

  • Addin= g glucagon brings fat-burning and energy expenditure (the retatrutide upg= rade)

  • Addin= g amylin brings extended satiety and slowed gastric emptying from a diffe= rent pathway

  • Addin= g calcitonin brings longer-duration satiety, insulin sensitivity, and bon= e/joint protection

On paper, you=E2=80=99d be combining the best of every= thing that=E2=80=99s already working. The incretin backbone of tirzepatid= e, the glucagon fat-burning of retatrutide, and the amylin/calcitonin sat= iety plus bone protection of the DACRA class =E2=80=94 all in one molecul= e. The mechanism makes sense, which is a big part of why people are excit= ed.

=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=

WHAT=E2=80=99S CON=46IRMED VS. WHAT=E2=80=99S HYPE

=

Here=E2=80=99s where I want to pump the brakes a littl= e.

The Lilly Quintuple Story (Mostly Hype Right Now)

The version circulating on X, Reddit (r/GLP1ResearchTa= lk), and Instagram reels claims Lilly is unveiling animal data on a GLP-1= /GIP/glucagon/amylin/calcitonin quintuple at ADA Scientific Sessions on M= ay 29, 2026.

The reality check:

  • No of= ficial Eli Lilly press release exists for this compound

  • No pi= peline entry exists on Lilly=E2=80=99s public pipeline page

  • No na= med compound (no LY-number) has been disclosed

  • The b= uzz traces back to a handful of social media accounts that got amplified<= /p>

That doesn=E2=80=99t mean it=E2=80=99s fake. Lilly doe= sn=E2=80=99t announce preclinical assets until they have data in hand, so= it=E2=80=99s entirely plausible something drops at ADA. They already own= amylin chemistry through eloralintide, and they=E2=80=99ve proven they c= an design unimolecular polyagonists. The pieces are there.

But =E2=80=9Cplausible=E2=80=9D is not the same as =E2= =80=9Cconfirmed.=E2=80=9D

The Other Quintuple That=E2=80=99s Real (And Worth Kno= wing About)

There=E2=80=99s a second quintuple in the literature t= hat=E2=80=99s already published, and it proves the concept works in princ= iple.

It was presented at EASD 2025 in Vienna by Dr. Daniela= Liskiewicz from Helmholtz Zentrum M=C3=BCnchen. That molecule targets GL= P-1 + GIP + pan-PPAR (alpha, delta, gamma =E2=80=94 three PPAR isoforms =3D= five total targets). It uses a clever delivery mechanism where the PPAR = part is only released inside cells that express GLP-1 or GIP receptors, s= o it=E2=80=99s targeted rather than systemic.

Mouse models showed it outperformed GLP-1/GIP co-agoni= sm alone on both weight and glucose control.

This is academic preclinical work =E2=80=94 not owned = by Lilly, not in human trials =E2=80=94 but it demonstrates that pushing = past three receptor targets is a legitimate and productive research direc= tion. Different compound, same direction of travel.

=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=

THE CURRENT LANDSCAPE =E2=80=94 WHAT=E2=80=99S ACTUALL= Y IN TRIALS

To keep perspective on where the quintuple fits in, he= re=E2=80=99s what=E2=80=99s actually advancing right now.

Retatrutide (Triple Agonist)

The most advanced next-generation obesity drug current= ly in human trials.

  • TRIUM= PH-4 (Phase 3, December 2025): 28.7% weight loss at 68 weeks on the 12mg = dose, vs. 2.1% for placebo. Also delivered 76% improvement in WOMAC knee = pain scores.

  • TRANS= CEND-T2D-1 (Phase 3, March 2026): Up to 2.0% A1C reduction and 16.8% weig= ht loss at 40 weeks in type 2 diabetes patients

  • 7 add= itional Phase 3 readouts expected throughout 2026

  • Likel= y 2027 =46DA approval per GlobalData forecasts

  • Notab= le safety signal: dysesthesia in 20.9% of patients on the 12mg dose

Eloralintide (Amylin Agonist)

Lilly=E2=80=99s selective amylin agonist, building the= case for amylin as a standalone and combination target.

  • Phase= 2 (November 2025): 9.5% to 20.1% weight loss at 48 weeks

  • Phase= 3 enrollment planned by end of 2025

  • Being= evaluated both as monotherapy and complementary to incretin therapy

Orforglipron (Oral GLP-1)

Lilly=E2=80=99s small-molecule oral GLP-1 agonist, app= roved in April 2026 under the name =46oundayo.

  • =46ir= st oral GLP-1 that can be taken without food or water restrictions

  • ATTAI= N-1 Phase 3: 12.4% weight loss (27.3 lbs) at 72 weeks at the 36mg dose

  • =46DA= approved for obesity in April 2026 =E2=80=94 fastest NME approval since = 2002

This is the actual current pipeline. The quintuple, if= it=E2=80=99s real, sits well behind all of these.

=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=

WHY TIME IS THE KEY VARIABLE

Here=E2=80=99s what matters most for anyone following = this story. The excitement is warranted, but the timeline is not short.

If animal data drops at ADA in 5 weeks, that=E2=80=99s= mouse data. =46rom mouse preclinical to approved human drug is historica= lly 8-12 years. Even in this accelerated environment, we=E2=80=99re talki= ng years before any of this matters clinically.

Retatrutide itself isn=E2=80=99t approved yet. It has = seven more Phase 3 readouts coming in 2026, with likely 2027 =46DA approv= al. The triple agonist is the story of the next 12-18 months. The quintup= le is the story of the early 2030s at the earliest.

Many preclinical compounds never make it to humans. Th= e history of drug development is full of animal models that looked amazin= g and then failed in translation. We should expect that possibility with = any new molecule.

The dysesthesia signal in retatrutide =E2=80=94 the ab= normal sensation side effect that appeared in 20.9% of patients on the hi= ghest dose =E2=80=94 shows that even well-designed polyagonists can surfa= ce new safety signals when they hit humans. More receptor targets means m= ore potential for unexpected interactions. That=E2=80=99s a real consider= ation for the quintuple concept.

=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=

A NOTE =46OR THE RESEARCH PEPTIDE COMMUNITY

I already know what=E2=80=99s coming =E2=80=94 people = are going to start searching for =E2=80=9Cquintuple agonist=E2=80=9D on v= endor sites after this buzz.

Don=E2=80=99t waste your time. If you see one listed, = it=E2=80=99s fake. There=E2=80=99s no public sequence, no structure, noth= ing to verify against. Anyone claiming to have a quintuple right now is s= elling you vibes.

The research peptide market always follows clinical sc= ience with a lag:

  • Retat= rutide is only now becoming broadly available because the sequence has be= en public for years

  • Tirze= patide took time after Phase 2 data came out

  • Any r= eal quintuple =E2=80=94 even if Lilly announces something verifiable in M= ay =E2=80=94 wouldn=E2=80=99t be meaningfully accessible in the research = space for a long time

  • Anyth= ing claiming to be a quintuple before that is a scam

=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=

BOTTOM LINE

The progression from dual to triple to quintuple is on= e of the most exciting trajectories in modern metabolic medicine.

What makes the quintuple concept interesting:

  • Each = receptor in the rumored stack solves a distinct problem

  • The m= echanisms are complementary, not redundant

  • Calci= tonin specifically could address issues nobody has solved yet =E2=80=94 b= one density loss from rapid weight loss, durability of appetite suppressi= on, and joint protection

  • The t= rajectory of the field supports the idea that more targets, carefully com= bined, can push efficacy higher

What to keep in mind:

  • The L= illy quintuple is currently social media buzz, not confirmed pipeline

    =

  • Even = if animal data drops at ADA in 5 weeks, it=E2=80=99s still mouse data

    =

  • Mouse= -to-market is typically 8-12 years

  • Retat= rutide is what=E2=80=99s actually arriving soon

  • Elora= lintide is what=E2=80=99s actually advancing through Phase 3 for amylin

  • The q= uintuple, if real, is a late-decade story

The most important thing to do right now is stay curio= us and stay patient. Let the science play out. Don=E2=80=99t build expect= ations around compounds that haven=E2=80=99t even had human trials yet. I= =E2=80=99ll cover whatever drops at ADA on May 29 when it happens.

=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=

KEY RE=46ERENCES (=46OR DEEPER READING)

  • Jastr= eboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity = =E2=80=94 A Phase 2 Trial. N Engl J Med. 2023;389:514-526

  • Eli L= illy. Retatrutide TRIUMPH-4 Phase 3 results press release. December 11, 2= 025. investor.lilly.com

  • Eli L= illy. Retatrutide TRANSCEND-T2D-1 Phase 3 results press release. March 19= , 2026. investor.lilly.com

  • Eli L= illy. Eloralintide Phase 2 results press release (published simultaneousl= y in The Lancet). November 2025

  • Liski= ewicz D, et al. GLP-1R/GIPR/Pan-PPAR quintuple agonist presentation. EASD= 2025 Annual Meeting, Vienna

  • Medsc= ape coverage: =E2=80=9CNovel Quintuple Agonist for Weight Loss, Glucose C= ontrol=3F=E2=80=9D September 29, 2025. medscape.com

  • News-= Medical coverage: =E2=80=9CNew quintuple agonist shows promise for treati= ng obesity and type 2 diabetes.=E2=80=9D September 21, 2025. news-medical= .net

  • Andre= assen KV, et al. Research on Dual Amylin and Calcitonin Receptor Agonists= (DACRAs, KBP-042, KBP-089) =E2=80=94 various publications

  • Eli L= illy pipeline page (no quintuple currently listed): lilly.com/science/res= earch-development/pipeline

=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=

=46or research use only. Not intended for human consum= ption or medical use. Always consult qualified professionals regarding an= y health-related decisions.

Upgrade to p= aid

You're= currently a free subscriber to Research Radar. =46or the full experience, upgrade your subscription.

Up= grade to paid

&=23160;=
Share
&=23160;=
&=23160;=
3D=22=22Like
3D=22=22=Comment
3D=22=22Restack
&=23160;=

=C2=A9 2026 Derek Pruski
548 Market Street PMB 72296, San =46rancisco, CA 94104
Unsubscribe

3D=22Start
3D=3D=22=22
--69eb7354_7ef7f3d0_1f43--